Is trazodone appropriate for treating tremor in an adult without known Parkinsonian disease, and what is the recommended dosing regimen?

Trazodone is NOT Appropriate for Treating Tremor

Trazodone should not be used for treating tremor (shaking) in adults, as it lacks robust evidence for efficacy and carries significant risks including orthostatic hypotension, sedation, and bleeding complications that outweigh any potential benefit. 1

Evidence Against Use for Tremor

The available evidence for trazodone in tremor management is extremely limited and contradictory:

• Weak and outdated research: A 1986 multicentric double-blind study showed no significant improvement in parkinsonian tremor, multiple sclerosis tremor, psychogenic tremor, or hyperthyroid tremor. Only 5 of 6 patients with essential tremor showed improvement (p<0.025), but this represents a tiny sample size from nearly 40 years ago 2

• Not FDA-approved for tremor: Trazodone is FDA-approved only for major depressive disorder in adults. The dosing regimen (150-400 mg/day for outpatients, up to 600 mg/day for inpatients) is specifically for depression treatment 1

• Contradictory historical claims: While a 1981 review mentioned trazodone "has been reported to be of value in tremors," this was not substantiated with rigorous evidence 3. A 1986 review suggested it might be preferable in elderly patients with tremor, but only in the context of treating depression—not tremor itself 4

Significant Safety Concerns

The FDA label highlights multiple serious adverse effects that make trazodone particularly problematic for tremor patients:

• Orthostatic hypotension and syncope: Can cause falls, especially dangerous in elderly patients who commonly present with tremor 1
• Cognitive and motor impairment: Causes somnolence and sedation that impairs mental and physical abilities—counterproductive when treating a movement disorder 1
• Increased bleeding risk: Particularly concerning with concomitant antiplatelet or anticoagulant use 1
• Discontinuation syndrome: Includes tremor itself as a withdrawal symptom, potentially worsening the original complaint 1

Clinical Context: When Tremor Meets Depression

The only scenario where trazodone might be considered is when a patient has both significant depression and tremor:

• Recent expert consensus (2026) suggests trazodone may have a role in Parkinson's disease patients with comorbid depression, but this is for treating the depression, not the tremor 5
• In early PD with mood alterations and anxiety, trazodone is listed as one option among mood stabilizers and tricyclics 5
• The 2026 tremor management review in PD does not recommend trazodone as a tremor-specific therapy 6, 7

Common Pitfall to Avoid

Do not prescribe trazodone off-label for tremor based on its sedative properties or outdated literature. The evidence is insufficient, and the risk-benefit ratio is unfavorable. If a patient has isolated tremor without depression, pursue evidence-based tremor treatments (beta-blockers for essential tremor, dopaminergic therapy for PD tremor, or interventional approaches for refractory cases).

Bottom Line Algorithm

For isolated tremor without depression:

• Do NOT use trazodone
• Pursue appropriate tremor-specific therapies based on etiology

For tremor WITH significant comorbid depression:

• Consider trazodone primarily as an antidepressant (150-400 mg/day in divided doses, taken with food) 1
• Monitor closely for orthostatic hypotension and falls
• Do not expect meaningful tremor improvement
• Gradual dose titration starting at 150 mg/day, increasing by 50 mg every 3-4 days as tolerated 1